Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00260598 · ClinicalTrials.gov registry record · Phase 2
LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer
A Phase 2 study, sponsored by University of Pittsburgh.
- Terminated
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
NCT00260598: Clinical Trial Phase 2 study, sponsored by University of Pittsburgh.
NCT00260598 is a Phase 2 study that was terminated before completion, run by University of Pittsburgh. The registered enrollment target is 142 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00260598, a Phase 2 study, was terminated before completion, sponsored by University of Pittsburgh.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the usefulness and accuracy of the "LIFE-Lung Bronchoscopy" to identify early changes in lung tissues that show precancerous, cancer in situ (just beginning and not spread) and microscopic invasive cancer lesions versus the ability of the standard "White Light Bronchoscopy" to identify the same. This will be done as a part of routine monitoring bronchoscopy. Patients who have had a surgical resection of non-small cell lung cancer (NSCLC) and with no current evidence of disease (NED) will be eligible. Also eligible are patients who have had head or neck squamous cell carcinoma with radical head and/or neck dissection and who are currently NED. Patients with severe chronic, obstructive, pulmonary disease shown by pulmonary function testing abnormalities will also be eligible. In addition to the specialized bronchoscopy, doctors will be investigating the use of imaging spectroscopy. This is using an optical (visualizing) procedure to measure the light reflected back from tissue. Different lesions and normal tissues reflect light differently and in specific color wavelengths. By using measurements over time (different examinations/bronchoscopies) very small changes can be seen. This may allow eventually for very early diagnosing of precancerous or cancer in situ lesions, allowing for earlier treatment.
Interventions
- PROCEDURE LIFE Bronchoscopy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 1998-08 |
| Est. Completion | 2017-03 |
| Phase | Phase 2 |
Why NCT00260598 stopped before completion
NCT00260598 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which LIFE Bronchoscopy is the first listed.
NCT00260598 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00260598 about?
NCT00260598 is a clinical study titled "LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer". The purpose of the study is to evaluate the usefulness and accuracy of the "LIFE-Lung Bronchoscopy" to identify early changes in lung tissues that show precancerous, cancer in situ (just beginning and not spread) and microscopic invasive cancer lesions versus the ability of the standard "White Light...
What is the current status of trial NCT00260598?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 1998-08. Estimated completion is 2017-03.
What interventions are being tested in trial NCT00260598?
The interventions under investigation include: LIFE Bronchoscopy (PROCEDURE).
Who is sponsoring clinical trial NCT00260598?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00260598's enrollment target sits among peer trials
142 507th of 2000 higher than 1,491 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia